Hepatitis C

ABSTRACT

Hepatitis C virus (HCV) is a leading cause of end-stage liver disease worldwide and the most common indication for liver transplantation in the United States and Europe. HCV nearly always recurs in liver-transplanted patients, and 10 to 25% of them develop cirrhosis within 5 to 10 years. One of the strategies suggested to limit virological HCV recurrence is pretransplant antiviral treatment, but studies are warranted on the pharmacokinetics of antiviral drugs in cirrhotic patients, the benefits of fixed or escalating antiviral drug dosage schedules, the duration of the treatment, and the indications for using growth factors. Several risk factors are associated with a more aggressive recurrent HCV and early allograft failure, such as an older donor age. The relationship between immunosuppression and fibrosis progression in HCV recurrence remains uncertain. Concerning the antiviral treatment, treating established recurrent disease with a combination of interferon and ribavirin has been the mainstay of management to date, but when it is best to start and how to manage the side effects are still controversial issues. Antiviral treatment should be started once the disease has been confirmed by a biopsy when the fibrosis develops, providing that ongoing acute or chronic rejection, biliary obstruction, vascular damage, autoimmune diseases and sepsis, and any other standard contraindications for antiviral therapy, have been excluded. HCV recurrence after liver transplantation may well lead to graft failure and become an indication for retransplantation, but this is done in a relatively small number of cases, accounting for only 3 to 5% of retransplanted patients, since retransplantation is associated with much worse results than primary liver transplant procedures. We must be prepared for the fact that increasing numbers of HCV-positive recipients with allografts failing due to recurrent HCV will be asking to be retransplanted—and we do not know yet how to respond to this request.

KEYWORDS

HCV recurrence - liver fibrosis progression - antiviral therapy

REFERENCES

• 1 Organ Procurement and Transplantation Network .Current U.S. waiting list candidates for liver transplant. Available at: http://www.optn.org/latestData/rtpData.asp Accessed August 23, 2008
• 2 Adam R, McMaster P, O'Grady J G et al.. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.  Liver Transpl. 2003;  9 1231-1243
• 3 Forman L M, Lewis J D, Berlin J A et al.. The association between hepatitis C infection and survival after orthotopic liver transplantation.  Gastroenterology. 2002;  122 889-896
• 4 Féray C, Caccamo L, Alexander G J et al.. European Collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.  Gastroenterology. 1999;  117 619-625
• 5 Thomas R M, Brems J J, Guzman-Hartman G et al.. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.  Liver Transpl. 2003;  9 905-915
• 6 Crippin J S, McCashland T, Terrault N, Sheiner P, Charlton M R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.  Liver Transpl. 2002;  8 350-355
• 7 Forns X, García-Retortillo M, Serrano T et al.. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.  J Hepatol. 2003;  39 389-396
• 8 Everson G T, Trotter  J, Forman L et al.. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.  Hepatology. 2005;  42 255-262
• 9 Helbling B, Jochum W, Stamenic I et al.. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.  J Viral Hepat. 2006;  13 762-769
• 10 Di Marco V, Almasio P L, Ferraro D et al.. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.  J Hepatol. 2007;  47 484-491
• 11 Iacobellis A, Siciliano M, Perri F et al.. Peginterferon alpha-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.  J Hepatol. 2007;  46 206-212
• 12 Bruno S, Stroffolini T, Colombo M et al.. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.  Hepatology. 2007;  45 579-587
• 13 Mutimer D J, Gunson B, Chen J. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus.  Transplantation. 2006;  81 7-14
• 14 Rayhill S C, Wu Y M, Katz D A. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.  Transplantation. 2007;  84 331-339
• 15 Grazi G L, Cescon M, Ravaioli M, Corti B, Pinna A D. Successful liver transplantation from a 95-year-old donor to a patient with MELD score 36 and delayed graft arterialization.  Am J Transplant. 2008;  8 725-726
• 16 Khapra A P, Agarwal K, Fiel M I et al.. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts.  Liver Transpl. 2006;  12 1496-1503
• 17 Segev D L, Kucirka L M, Nguyen G C et al.. Effect modification in liver allografts with prolonged cold ischemic time.  Am J Transplant. 2008;  8 658-666
• 18 Hong J C, Busuttil R W. Cold ischemia time and liver graft survival.  Am J Transplant. 2008;  8 481-482
• 19 Burra P, Loreno M, Russo F P et al.. Donor livers with steatosis are safe to use in HCV-positive recipients.  Liver Transpl. 2009;  , In press
• 20 Botha J F, Thompson E, Gilroy R et al.. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.  Liver Int. 2007;  27 758-763
• 21 Briceño J, Ciria R, Pleguezuelo M et al.. Contribution of marginal donors to liver transplantation for hepatitis C virus infection.  Transplant Proc. 2007;  39 2297-2299
• 22 Muiesan P, Girlanda R, Jassem W et al.. Single-center experience with liver transplantation from controlled non-heartbeating donors: a viable source of grafts.  Ann Surg. 2005;  242 732-738
• 23 Terrault N A, Shiffman M L, Lok A S et al.. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.  Liver Transpl. 2007;  13 122-129
• 24 Humar A, Horn K, Kalis A et al.. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?.  Am J Transplant. 2005;  5 399-405
• 25 Lawal A, Ghobrial R, Te H et al.. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation.  Transplant Proc. 2007;  39 3261-3265
• 26 Saraf N, Fiel M I, Deboccardo G, Emre S, Schiano T D. Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation.  Liver Transpl. 2007;  13 913-917
• 27 Bilbao I, Dopazo C, Lazaro J L et al.. Our experience in liver transplantation in patients over 65 yr of age.  Clin Transplant. 2008;  22 82-88
• 28 Cameron A M, Ghobrial R M, Hiatt J R et al.. Effect of nonviral factors on hepatitis C recurrence after liver transplantation.  Ann Surg. 2006;  244 563-571
• 29 Belli L S, Burroughs A K, Burra P et al.. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.  Liver Transpl. 2007;  13 733-740
• 30 Jonsson J R, Barrie H D, O'Rourke P, Clouston A D, Powell E E. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C.  Hepatology. 2008;  48 80-87
• 31 Seo S, Maganti K, Khehra M et al.. De novo nonalcoholic fatty liver disease after liver transplantation.  Liver Transpl. 2007;  13 844-847
• 32 Petta S, Cammà C, Marco V D et al.. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.  Am J Gastroenterol. 2008;  103 1136-1144
• 33 Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic hepatitis C.  J Hepatol. 2008;  48 657-665
• 34 Burra P, Mioni D, Cecchetto A et al.. Histological features after liver transplantation in alcoholic cirrhotics.  J Hepatol. 2001;  34 716-722
• 35 Belli L S, Zavaglia C, Alberti A B et al.. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation.  Hepatology. 2000;  31 1345-1350
• 36 Belli L S, Burra P, Poli F et al.. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation.  Gastroenterology. 2006;  130 695-702
• 37 Fishman J A, Rubin R H. Infection in organ-transplant recipients.  N Engl J Med. 1998;  338 1741-1751
• 38 Lucas M, Vargas-Cuero A L, Lauer G M et al.. Pervasive influence of hepatitis c virus on the phenotype of antiviral CD8+ T cells.  J Immunol. 2004;  172 1744-1753
• 39 Nebbia G, Mattes F M, Cholongitas E et al.. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation.  Liver Transpl. 2007;  13 130-135
• 40 Teixeira R, Pastacaldi S, Davies S et al.. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation.  Transplantation. 2000;  70 1454-1458
• 41 Burak K W, Kremers W K, Batts K P et al.. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.  Liver Transpl. 2002;  8 362-369
• 42 Humar A, Kumar D, Raboud J et al.. Interactions between cytomegalovirus, human herpes virus-6, and the recurrence of hepatitis C after liver transplantation.  Am J Transplant. 2002;  2 461-466
• 43 Yilmaz N, Shiffman M L, Stravitz R T et al.. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.  Liver Transpl. 2007;  13 975-983
• 44 Biggins S W, Terrault N A. Treatment of recurrent hepatitis C after liver transplantation.  Clin Liver Dis. 2005;  9 505-523
• 45 Brown Jr R S. Hepatitis C and liver transplantation.  Nature. 2005;  436 973-978
• 46 Shiffman M L, Vargus H E, Everson G T. Controversies in the management of hepatitis C virus infection after liver transplantation.  Liver Transpl. 2003;  9 1129-1144
• 47 Sebagh M, Rifai K, Feray C et al.. All liver recipients benefit from the protocol 10-year liver biopsies.  Hepatology. 2003;  37 1293-1301
• 48 Feray C. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.  J Hepatol. 2004;  41 862-863
• 49 Guido M, Fagiuoli S, Tessari G et al.. Histology predicts cirrhotic evolution of post transplant hepatitis C.  Gut. 2002;  50 697-700
• 50 Baiocchi L, Angelico M, Petrolati A et al.. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease.  Am J Transplant. 2008;  8 673-678
• 51 Dixon L R, Crawford J M. Early histologic changes in fibrosing cholestatic hepatitis C.  Liver Transpl. 2007;  13 219-226
• 52 Tretheway D, Jain A, LaPoint R et al.. Should trichrome stain be used on all post-liver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score?.  Liver Transpl. 2008;  14 695-700
• 53 Yerian L. Identifying activated hepatic stellate cells in chronic and posttransplant recurrent hepatitis C.  Liver Transpl. 2008;  14 756-758
• 54 Carotti S, Morini S, Corradini S G et al.. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C.  Liver Transpl. 2008;  14 806-814
• 55 Rigamonti C, Donato M F, Fraquelli M et al.. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation.  Gut. 2008;  57 821-827
• 56 Talwalkar J A, Yin M, Fidler J L et al.. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications.  Hepatology. 2008;  47 332-342
• 57 Samonakis D N, Triantos C K, Thalheimer U et al.. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation.  Liver Transpl. 2005;  11 386-395
• 58 Sheiner P A, Schwartz M E, Mor E et al.. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.  Hepatology. 1995;  21 30-34
• 59 Rosen H R, Shackleton C R, Higa L et al.. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.  Am J Gastroenterol. 1997;  92 1453-1457
• 60 Berenguer M, Prieto M, Córdoba J et al.. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.  J Hepatol. 1998;  28 756-763
• 61 Gane E J, Portmann B C, Naoumov N V et al.. Long-term outcome of hepatitis C infection after liver transplantation.  N Engl J Med. 1996;  334 815-820
• 62 Kato T, Gaynor J J, Yoshida H et al.. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.  Transplantation. 2007;  84 829-835
• 63 Papatheodoridis G V, Davies S, Dhillon A P et al.. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis.  Transplantation. 2001;  72 412-418
• 64 Segev D L, Sozio S M, Shin E J et al.. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials.  Liver Transpl. 2008;  14 512-525
• 65 Vivarelli M, Burra P, La Barba G et al.. Influence of steroids on HCV recurrence after liver transplantation: a prospective study.  J Hepatol. 2007;  47 793-798
• 66 Martin P, Busuttil R W, Goldstein R M et al.. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.  Liver Transpl. 2004;  10 1258-1262
• 67 Walter T, Dumortier J, Guillaud O et al.. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center.  Liver Transpl. 2007;  13 294-301
• 68 Marcos A, Eghtesad B, Fung J J et al.. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus.  Transplantation. 2004;  78 966-971
• 69 Terrault N A. Treatment of recurrent hepatitis C in liver transplant recipients.  Clin Gastroenterol Hepatol. 2005;  3 S125-S131
• 70 Carrión J A, Navasa M, García-Retortillo M et al.. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.  Gastroenterology. 2007;  132 1746-1756
• 71 Angelico M, Petrolati A, Lionetti R et al.. A randomized study on peg-interferon alpha-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.  J Hepatol. 2007;  46 1009-1017
• 72 Dumortier J, Scoazec J Y, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alpha-2b and ribavirin combination.  J Hepatol. 2004;  40 669-674
• 73 Rodriguez-Luna H, Khatib A, Sharma P et al.. Treatment of recurrent hepatitis C infection after liver transplantation with a combination of pegylated interferon alpha2b and ribavirin: an open-label series.  Transplantation. 2004;  77 190-194
• 74 Sharma P, Marrero J A, Fontana R J et al.. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.  Liver Transpl. 2007;  13 1100-1108
• 75 Chalasani N, Manzarbeitia C, Ferenci P et al.. Peginterferon alpha-2a for hepatitis C after liver transplantation: two randomized, controlled trials.  Hepatology. 2005;  41 289-298
• 76 Shergill A K, Khalili M, Straley S et al.. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.  Am J Transplant. 2005;  5 118-124
• 77 Samuel D, Bizollon T, Feray C et al.. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.  Gastroenterology. 2003;  124 642-650
• 78 Zimmermann T, Böcher W O, Biesterfeld S et al.. Efficacy of an escalating-dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.  Transpl Int. 2007;  20 583-590
• 79 Oton E, Barcena R, Moreno-Planas J M et al.. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin.  Am J Transplant. 2006;  6 2348-2355
• 80 Heydtmann M, Freshwater D, Dudley T et al.. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation.  Am J Transplant. 2006;  6 825-833
• 81 Berardi S, Lodato F, Gramenzi A et al.. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?.  Gut. 2007;  56 237-242
• 82 Hanouneh I A, Miller C, Aucejo F et al.. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.  Liver Transpl. 2008;  14 53-58
• 83 Xirouchakis E, Triantos C, Manousou P et al.. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.  J Viral Hepat. 2008;  10 699-709
• 84 Bizollon T, Pradat P, Mabrut J Y et al.. Histological benefit of retreatment by pegylated interferon alpha-2b and ribavirin in patients with recurrent hepatitis C virus infection post-transplantation.  Am J Transplant. 2007;  7 448-453
• 85 Terrault N A. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation.  Liver Transpl. 2003;  9 S95-S100
• 86 Sugawara Y, Makuuchi M, Matsui Y et al.. Preemptive therapy for hepatitis C virus after living-donor liver transplantation.  Transplantation. 2004;  78 1308-1311
• 87 Sheiner P A, Schluger L K, Emre S et al.. Retransplantation for recurrent hepatitis C.  Liver Transpl Surg. 1997;  3 130-136
• 88 Charlton M, Seaberg E, Wiesner R et al.. Predictors of patient and graft survival following liver transplantation for hepatitis C.  Hepatology. 1998;  28 823-830
• 89 Ghobrial R M, Farmer D G, Baquerizo A et al.. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.  Ann Surg. 1999;  229 824-831
• 90 Ghobrial R M. Retransplantation for recurrent hepatitis C.  Liver Transpl. 2002;  8 S38-S43
• 91 Rosen H R, Madden J P, Martin P. A model to predict survival following liver retransplantation.  Hepatology. 1999;  29 365-370
• 92 Rosen H R, Martin P. Hepatitis C infection in patients undergoing liver retransplantation.  Transplantation. 1998;  66 1612-1616
• 93 Northup P G, Pruett T L, Kashmer D M et al.. Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index.  Am J Transplant. 2007;  7 1984-1988
• 94 Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection.  Am J Transplant. 2008;  8 404-411